|
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors
|
- Second New Drug Application ("NDA") approved for Sulanda in China - - The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51% in patients with advanced pancre...
Full "IntellAsia: Resources" article
|
|